| Literature DB >> 31665142 |
Ida Maria Maximina Fernandes-Charpiot1, Cassia Fernanda Estofolete2, Heloisa Cristina Caldas1, Gabriela Rodrigues de Souza1, Rita de Cássia Martins Alves da Silva1, Maria Alice Sperto Ferreira Baptista1, Mauricio Lacerda Nogueira2, Mario Abbud-Filho1,3.
Abstract
Dengue infection (DI) is the most important arboviral infection in the world. The majority of immunocompetent patients will have asymptomatic or mild infections, but the degree of dengue severity in kidney transplant recipients (KTx) is unknown. In this study, we report the clinical profile and outcomes of 39 dengue cases in KTx. From a total of 1,186 KTx outpatients in follow-up we reviewed clinical and laboratory records of 60 (5%) patients admitted with suspected DI initially screened by NS-1, IgM, and when possible, multiplex nested PCR. The prevalence of DI in KTx was 3% (39/1,118), with symptoms leading to hospital admission being fever, myalgia, malaise, and headache. Laboratory tests showed leucopenia, thrombocytopenia, and liver enzyme elevation. DI was confirmed by positivity of NS-1 (33%), IgM (69%), and/or RT-PCR (59%). Twenty-three patients (59%) had dengue with warning signs, and 15% had severe dengue, 2 of them with a fatal course. Acute graft dysfunction occurred in 59% (mean nadir serum creatinine: 2.9 ± 2.6mg/dL), 4 of them requiring dialysis. CMV coinfection diagnosed in 19% of the cases and patients was associated with worse clinical presentation. Our results suggest that KTx with DI presented initial physical and laboratorial profile similar to the general population. However, DI in KTx seems to have a higher risk for graft dysfunction, severe dengue, and death. Because CMV coinfection aggravates the DI clinical presentation and recovery, it must be evaluated in all cases.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31665142 PMCID: PMC6821097 DOI: 10.1371/journal.pone.0219117
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic characteristics of 39 transplant recipients at initial diagnosis of dengue infection.
| Baseline characteristics | Mean ± SD or n (%) |
|---|---|
| Age (years) | 50 ± 14 |
| Female gender | 22 (56%) |
| Ethnicity (Caucasian) | 30 (77%) |
| Polycystic kidney disease | 8 (21%) |
| Hypertension | 6 (15%) |
| Glomerulopathy | 6 (15%) |
| Diabetes mellitus | 4 (10%) |
| Unknown | 15 (39%) |
| Deceased | 22 (56%) |
| Living | 17 (44%) |
| Basiliximab | 18 (46%) |
| Thymoglobulin | 04 (10%) |
| None | 17 (44%) |
| Calcineurin inhibitors | 27 (70%) |
| mTOR inhibitors | 15 (39%) |
| Micophenolic acid | 22 (56%) |
| Steroid | 39 (100%) |
| Acute rejection prior to DI diagnosis | 8 (20%) |
| CMV infection prior to DI diagnosis | 12 (31%) |
| Time since transplant (months) | 65 ± 62 |
| Hospitalization required | 29 (74%) |
| Hospitalization time (days) | 7 ± 6 |
| Time onset symptoms (days) | 5 ± 4 |
| Follow-up time after DI (months) | 28 ± 24 |
Clinical Characteristics of Dengue Infection in KTx at Admission.
| Characteristics Total n = 39 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical findings (n/39) | n (%) | Mean ± SD | |||||||||
| Fever | 34 (87) | - | |||||||||
| Myalgia | 32 (82) | - | |||||||||
| Malaise | 27 (69) | - | |||||||||
| Headache | 24 (62) | - | |||||||||
| Nauseas | 18 (46) | - | |||||||||
| Anorexia | 18 (46) | - | |||||||||
| Diarrhea | 15 (39) | - | |||||||||
| Arthralgia | 9 (23) | - | |||||||||
| Rash | 6 (15) | - | |||||||||
| - | |||||||||||
| Cytomegalovirus | 6 (19) | - | |||||||||
| Hepatitis (B/C) | none | - | |||||||||
| Hemoconcentration | 3 (7.6) | - | |||||||||
| Leukopenia | 26 (67) | 3,481 ± 2,010/mm3 | |||||||||
| Thrombocytopenia | 29 (74) | 117,665 ± 90,943/mm3 | |||||||||
| Increased AST | 21 (65) | 75 ± 59 UI/l | |||||||||
| Increased ALT | 19 (59) | 71 ± 87 UI/l | |||||||||
| Increased GGT | 22 (78) | 168 ± 240 UI/l | |||||||||
| Hemoglobin (mg/dL) | - | 12 ± 2 | |||||||||
| Hematocrit (%) | - | 38 ± 5.7 | |||||||||
| Creatinine (mg/dL) | - | 2.9 ± 2.6 | |||||||||
| 23 (59) | - | ||||||||||
| Persistent vomiting | 7 (57) | - | |||||||||
| Abdominal pain | 9 (39) | - | |||||||||
| Hypotension | 8 (35) | - | |||||||||
| Bleeding | 7 (30) | - | |||||||||
| Clinical fluid accumulation (ascites) | 2 (9) | - | |||||||||
| Lethargy, restlessness | 1 (4) | - | |||||||||
| 6 (15) | - | ||||||||||
| Severe plasma leakage leading to shock | 1 (2.5) | - | |||||||||
| Severe bleeding (hemorrhagic stroke) | 1 (2.5) | - | |||||||||
| Severe organ involvement | 4 (10) | - | |||||||||
| Mean serum creatinine (mg/dL) | |||||||||||
| Last baseline | - | 1.7 ± 0.8 | |||||||||
| Nadir | - | 2.9 ± 2.6 | |||||||||
| Day 30 after discharged | - | 1.5 ± 0.7 | |||||||||
| Day 6 months after DI | - | 1.6 ± 0.8 | |||||||||
| Acute graft dysfunction | 23 (59) | - | |||||||||
| Required renal replacement therapy | 4 (17) | - | |||||||||
| Renal function after 30 days | |||||||||||
| Completely recovery | 16 (70) | - | |||||||||
| Partial recovery | 4 (17) | - | |||||||||
| Graft loss | 1 (3) | - | |||||||||
| Death | 2 (5) | - | |||||||||
* AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT: gamma-glutamyltransferase. Reference values: Hb: 12–17 mg/dl; Ht: 40–55%; Leukocytes: 4,000–11,000/mm3; platelets: 150,000–300,000/mm3; Cr: 0.7–1,2 mg/dl; AST: 40 UI/l; ALT: 41 UI/l; GGT: 1–60 UI/l.
** Severe organ involvement: pancreas (n = 1, acute pancreatitis), kidney (n = 1, graft loss), and central nervous system (n = 2, encephalitis)
*** Death causes: hemorrhagic stroke (1), shock (1)
† Cytomegalovirus: n = 31; AST and ALT: n = 32; GGT: n = 28
Confirmatory diagnosis of dengue in each KTx case.
| Confirmatory Laboratory Method | |||||
|---|---|---|---|---|---|
| Patient | NS1 detection | IgM—ELISA | RT-PCR | CSF | Year |
| 13/18 (72%) | 27/32 (84%) | 22/28 (79%) | 2/2 (100%) | ||
| 1 | ND | ND | ND | 2007 | |
| 2 | ND | ND | ND | 2007 | |
| 3 | ND | ND | 2010 | ||
| 4 | Negative | ND | 2010 | ||
| 5 | ND | ND | ND | 2010 | |
| 6 | ND | 2011 | |||
| 7 | ND | ND | 2013 | ||
| 8 | Not amplified | ND | 2013 | ||
| 9 | ND | 2013 | |||
| 10 | ND | ND | ND | 2013 | |
| 11 | ND | Negative | ND | 2013 | |
| 12 | ND | ND | ND | 2013 | |
| 13 | ND | Inconclusive | ND | 2013 | |
| 14 | Negative | Negative | ND | 2013 | |
| 15 | ND | 2014 | |||
| 16 | ND | Negative | ND | 2015 | |
| 17 | ND | ND | 2015 | ||
| 18 | ND | ND | 2015 | ||
| 19 | ND | ND | 2015 | ||
| 20 | ND | ND | 2015 | ||
| 21 | Negative | ND | 2015 | ||
| 22 | Negative | Negative | ND | 2015 | |
| 23 | ND | Negative | ND | 2015 | |
| 24 | Negative | ND | 2015 | ||
| 25 | ND | ND | ND | 2015 | |
| 26 | Negative | ND | 2015 | ||
| 27 | ND | Negative | ND | 2015 | |
| 28 | ND | ND | ND | 2015 | |
| 29 | ND | ND | ND | 2015 | |
| 30 | Negative | Negative | 2015 | ||
| 31 | ND | ND | ND | 2016 | |
| 32 | ND | ND | 2016 | ||
| 33 | ND | ND | ND | 2016 | |
| 34 | ND | ND | 2016 | ||
| 35 | ND | ND | 2016 | ||
| 36 | ND | 2016 | |||
| 37 | ND | ND | 2016 | ||
| 38 | ND | ND | ND | 2016 | |
| 39 | ND | ND | 2016 | ||
ND: not done; CSF: cerebrospinal fluid
** IgM serology (ELISA)
Dengue infection in KTx subgroup which developed CMV viremia compared with KTx subgroup with PCR negative.
| PCR CMV + (n = 6) | PCR CMV—(n = 25) | p-value | |
|---|---|---|---|
| Age (years) | 54 ± 12 | 51 ± 14 | 0.63 |
| Time since transplant (months) | 17 ± 33 | 65 ± 64 | 0.01 |
| Time onset symptoms (days) | 7 ± 5 | 4 ± 4 | 0.1 |
| Hospitalization time (days) | 15 ± 9 | 6 ± 5 | 0.003 |
| DI with warning signs | 5 (83%) | 14 (56%) | 0.3 |
| Severe dengue | 1 (17%) | 4 (16%) | 1 |
| Viral load of the CMV (UI) | 236–2,366 | negative to < 29 | - |
| Hemoglobin (mg/dl) | 12 ± 3 | 12 ± 2 | 1 |
| Leukocytes (cells/mm | 2 ± 57 | 3.5 ± 2 | 0.08 |
| Platelets (cells/mm3) | 42.6 ± 40.5 | 120.3 ± 92.6 | 0.005 |
| AST (UI/l) | 111 ± 79 | 72 ± 64 | 0.16 |
| ALT (ui/l) | 115 ± 116 | 67 ± 86 | 0.3 |
| Alkaline phosphatase (UI/l) | 192 ± 189 | 112 ± 107 | 0.2 |
| Gamma-glutamyltransferase (UI/l) | 448 ± 481 | 102 ± 88 | 0.005 |
| Creatinine (mg/dL) | 3 ± 1.5 | 2.6 ± 2 | 0.6 |
| Acute graft dysfunction | 5 (83%) | 15 (60%) | 0.38 |
| Graft loss | 0 | 1 (4%) | - |
| Death related to DI | 0 | 1 (4%) | - |
| Late death not related to DI or CMV | 4 (66%) | 2 (8%) | 0.007 |
*quantitative PCR (range)
#Reference values: Hemoglobin: 12–17 mg/dl; Leukocytes: 4,000–11,000/mm3; platelets: 150,000–300,000/mm3; Cr: 0.7–1.2 mg/dl; AST: 40 UI/l; ALT: 41 UI/l; AP: 40–130 UI/l; GGT: 1–60 UI/l.